Blood based monitoring for all solid organ tumours
Cancertrack utilises a blood-based analysis to detect cancer-related biomarkers with exceptional precision, specificity, and reliability. This innovative approach enables continuous monitoring of cancer, facilitating early detection of relapses or changes in tumour characteristics.
ABOUT CANCERTRACK
Cancertrack offers the flexibility to monitor the disease, recurrence, or changes in tumour characteristics as frequently as needed.
Features of cancertrack
Detection of circulating DNA, released into the patient's blood by cancer cells (ctDNA), can be performed, optionally combined with circulating tumour cells (CTCs).
Early-stage detection of tumour activity is facilitated
The medication is adjusted in real-time based on the test results
Furthermore, monitoring of non-visible metastases and tumours is conducted
Detection limits: 0.1% (Minor Allele Frequency)
Safe, straightforward, and economical
What can Cancertrack reveal?
FAQ
Why is early detection of molecular dynamics of cancer critical?
The molecular evolution of the tumour, including tumour size and molecular diversification, is a continuous process that can progress at high speed. Therefore, early detection of recurrence or drug resistance is essential to keep the cancer under control.
How frequently is it necessary to perform the test?
Cancertrack should ideally be performed at every important milestone in the fight against cancer and especially when the tumour has disappeared from conventional imaging / patient is under follow-up for recurrence monitoring, but usally every 3 - 12 months.
Sample requirement and Turn Around Time (TAT)
15 – 20 ml blood in DCGL and EDTA tubes
8 – 10 days from receipt of the sample
CONTACT
Cancer Profiling Australia
903/50 Clarence Street,
SYDNEY NSW 2000
PH +61 1300 282 482
FAX +61 2 8088 7097
Email: info@cancerprofiling.com.au